As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib

Table 4

Univariate and multivariate analyses of different type of adverse events for overall survival.

Adverse events	Patients (%)	Univatiate analyses		Multivariate analyses
		Unadjusted HR (95% CI)	Value	Adjusted HR (95% CI)	Value
≥1 grade of adverse events
Any	218 (92.8)	0.45 (0.26–0.76)	0.003	0.47 (0.27–0.82)	0.008
HFSR	182 (77.5)	0.59 (0.43–0.81)	0.001	0.70 (0.50–0.98)	0.038
Alopecia	156 (66.4)	0.79 (0.59–1.06)	0.122	0.75 (0.55–1.03)	0.076
Rash	124 (52.8)	0.99 (0.75–1.31)	0.944	0.81 (0.61–1.08)	0.154
Diarrhea	100 (42.6)	0.85 (0.64–1.22)	0.478	0.72 (0.53–0.97)	0.029
Fatigue	102 (43.4)	1.34 (1.01–1.77)	0.039	0.95 (0.70–1.28)	0.725
Voice change	46 (19.6)	1.08 (0.76–1.52)	0.679	0.69 (0.46–1.02)	0.062
Dental ulcer	26 (11.1)	0.79 (0.50–1.23)	0.295	0.74 (0.47–1.17)	0.198
Hypertension	29 (12.3)	0.84 (0.56–1.28)	0.425	0.92 (0.60–1.41)	0.704
≥2 grade of adverse events
Any	174 (74.0)	0.51 (0.38–0.70)	<0.001	0.42 (0.30–0.59)	<0.001
HFSR	125 (53.2)	0.43 (0.33–0.57)	<0.001	0.43 (0.32–0.58)	<0.001
Rash	61 (26.0)	0.89 (0.66–1.22)	0.478	0.75 (0.55–1.04)	0.081
Diarrhea	52 (22.1)	1.02 (0.74–1.41)	0.891	1.07 (0.76–1.50)	0.697
≥3 grade of adverse events
Any	59 (25.1)	0.73 (0.53–1.01)	0.060	0.65 (0.46–0.91)	0.013
HFSR	45 (19.1)	0.70 (0.48–1.00)	0.051	0.68 (0.47–1.00)	0.051

Abbreviations: HR, hazard ratio; CI, confidence interval; HFSR, hand-foot-skin reaction.